The genie of mRNA gene therapy injections is out of the bottle. Moderna’s new shot targets the common cold RSV, an extremely low-risk virus, and the FDA has granted fast-track designation for rapid approval.
This new shot will mostly target young children and older adults. No other RSV vaccine has ever been successful. Why the rush to saturate the human race with genetically modified injections designed to hack the immune system?
> Respiratory syncytial virus (RSV) — a respiratory virus that causes typically mild cold-like symptoms — is emerging out of season around the world
> Most children have been exposed to RSV by their second birthday and recover without incident. In rare cases, RSV can progress to pneumonia or bronchiolitis (inflammation of the small airways of the lungs)
> August 3, 2021, the U.S. Food and Drug Administration granted fast-track designation to Moderna for an mRNA-based injection against RSV
> As with coronavirus, previous efforts to develop an RSV vaccine have met with failure as test subjects have a tendency to die or become seriously ill when exposed to the wild virus, thanks to paradoxical immune enhancement (PIE), also known as antibody dependent enhancement (ADE)
Moderna’s RSV shot uses the same lipid nanoparticle as its COVID-19 injection. The mRNA will encode for a prefusion F glycoprotein, a protein that mediates the RSV virus’ entry into your cells and is known to elicit a neutralizing antibody response.
Read More: Moderna Launches Another mRNA-Based Injection Targeting The Common Cold RSV